Recent Company News

• 12:35 AM ET Oct 31, 2025
  

  Mitsubishi Chemical reports Q2 net income attributable ¥90.5B vs FactSet ¥81.97B [4 est, ¥36-109.70B] (¥809.6000, -34.9)

• 07:13 PM ET Oct 23, 2025
  

  StreetAccount Sector Preview - Japan Chemicals Jul-Sep Earnings

• 02:09 AM ET Oct 23, 2025
  

  Mitsubishi Tanabe Pharma receives complete response letter from FDA for ND0612 (¥856.3000, +6.3)

• 05:37 PM ET Oct 09, 2025
  

  Citi initiates 4042.JP, 4182.JP, 4183.JP, and 4188.JP

• 06:54 PM ET Oct 07, 2025
  

  JNJ notes FDA approval for SIMPONI (golimumab) for treatment of children living with moderately to severely active ulcerative colitis weighing at least 15 kg ($188.89, 0.00)

• 08:06 AM ET Sep 30, 2025
  

  Mineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial of Lorundrostat in obstructive sleep apnea and hypertension ($39.35, 0.00)

• 08:34 AM ET Sep 23, 2025
  

  Neurocrine Biosciences presents new post-hoc analysis: treatment with INGREZZA (valbenazine) capsules achieves earlier remission of Tardive Dyskinesia symptoms while reducing patient-reported disease burden ($146.62, 0.00)

• 09:04 AM ET Sep 05, 2025
  

  Mineralys Therapeutics announces new subgroup analyses from Phase 3 Launch-HTN trial evaluating blood pressure-lowering efficacy and safety of Lorundrostat ($33.12, 0.00)

• 10:54 PM ET Aug 20, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 08:06 AM ET Aug 04, 2025
  

  Akebia initiates Vafseo (vadadustat) post-marketing study in conjunction with large dialysis Organization ($3.72, 0.00)